Treatment of dyskinesia
US6740659B2 · kind B2 · utility
4Cited by
0References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 2, 2002 |
| Grant date | May 25, 2004 |
| Priority date | — |
| Expiry date | Aug 2, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.